EROSIVE-ULCERATIVE COMPLICATIONS OF ANTIPLATELET AND/OR ANTICOAGULANT THERAPY IN ELDERLY PATIENTS
Abstract
Patients with diseases of the cardiovascular system, in some cases require long-term or permanent therapy with antiplatelet and / or anticoagulant drugs, which increase the survival rate and are an integral component of a comprehensive treatment and prevention of a variety of these diseases. The diseases of the cardiovascular system such as coronary heart disease, atrial fibrillation, heart disease, hypertension, atherosclerosis vessels are accompanied by a high risk of intravascular thrombus and are common in elderly. The antithrombotic therapy is required in such cases. However the purpose of such therapy in patients of the older age group raises a number of issues. The Age (especially over 75 years) is a risk factor for both the development of thromboembolic complications, and gastrointestinal bleeding. The gastric secretion inhibitors can be used to protect the gastric mucosa in the case of the mucosal erosions in the antiplatelet and / or anticoagulant treatment.
About the Author
I. A. Komissarenko
State Budget Educational Institution of Higher Professional Education (SBEI HPE) A. I. Evdokimov Moscow State University of Medicine and Dentistry Ministry of Healthcare of Russia
Russian Federation
Russian Federation
References
1. Bombardier C., Laine L., Reicin A. et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis: VIGOR Study Group//N Engl J Med. 2000; 343: 1520-1528
2. Abraham N. S., Hartman C, Castillo D., Richardson P., Smalley W. Effectiveness of national provider prescription of PPI gastroprotection among elderly NSAID users//Am J Gastroenterol. 2008;103: 323-332
3. Максимов Р. С., Дмитриева Р. В., Деомидов Е. С., Максимова И Д. Профилактика инсульта при фибрилляции предсердий у пожилых пациентов // Бюллетень медицинских Интернет-конференций, Vol. 5, Issue 3, 2015, pp. 176-178
4. Wändell PE et al. Treating elderly AF patients with anticoagulation improves survival, more so than antiplatelets. 23-10-2014. http://www.pace-cme.org
5. Канорский С. Г. Антиаритмическая терапия у пациентов с пароксизмальной и персистирующей формами фибрилляции предсердий: определение достижимой цели и оценка имеющихся средств. Кардиология № 2, 2014, с. 70-74
6. Camm A. J., Kirchhof P., Lip G. Y. H. et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace. 2010; 12: 1360-1420.,
7. Camm A. J., Lip G. Y. H., De Caterina R. et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Europace. 2012; 14: 1385-1413.
8. Диагностика и лечение фибрилляции предсердий. Рекомендации РКО, ВНОА и АССХ, 2012
9. January C. T., Wann L. S., Alpert J. S. et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation 2014 Apr 10. [Epub ahead of print]].
10. Hart R. G., Pearce L. A., Aguilar M. I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857-867.
11. Stuart J. Connolly, M. D., Michael D. Ezekowitz, et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2009; 361:1139-1151
12. Manesh R. Patel, M. D., Kenneth W. Mahaffey et al. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. N Engl J Med 2011; 365:883-891
13. Christopher B. Granger, M. D., John H. Alexander, M. D. et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2011; 365:981-992
14. А. Л. Верткин, Е. И. Вовк, А. В. Наумов и соавт. Лечение и профилактика поражений слизистой оболочки желудочно-кишечного тракта в терапевтической практике. Клинические перспективы гастроэнтерологии, гепатологии», 2009, № 1, с. 35-41
15. Затейщиков Д. А., Зотова И. В. Дабигатран: перспективы клинического применения. Фарматека, 2011, № 15, с 30-34
16. С. В. Силуянов, Г. О. Смирнова, И. Г. Лучинкин Кровотечения из острых язв желудка и двенадцатиперстной кишки в клинической практике РМЖ. - Т. 17. - № 5. - 2009, с. 374.
17. Колобов C. B., Лоранская И. Д., Зайратьянц О. В. Эрозивно-язвенные поражения желудка и двенадцатиперстной кишки при остром инфаркте миокарда. Экспериментальная и клиническая гастроэнтерология. 2003, № 1, с. 95-97
18. Eikelboom J. W., Wallentin L., Connolly S. J. et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011;123:2363-2372
19. Шевелев В. И., Канорский С. Г. Сравнение трех методов антитромботической терапии у пожилых пациентов с неклапанной фибрилляцией предсердий. Кардиология 2012;7:56-60
20. Bytzer P, Connolly SJ, Yang S, et al. Analysis of upper gastrointestinal adverse events among patients given dabigatran in the RE-LY trial. Clin Gastroenterol Hepatol 2013;11:246-52
Review
For citations:
Komissarenko I.A. EROSIVE-ULCERATIVE COMPLICATIONS OF ANTIPLATELET AND/OR ANTICOAGULANT THERAPY IN ELDERLY PATIENTS. Experimental and Clinical Gastroenterology. 2016;(6):3-8. (In Russ.)
Views:
217
Email this article 